Download ALLHAT Publications - University of Texas School of Public Health

UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 1
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Publications
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic Versus Alpha-Blocker as First-Step
Antihypertensive Therapy: Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Hypertension 2003;42:239-246.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive
patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately
hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;
288:2998-3007.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive
patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT). JAMA 2000;283:1967-1975.
Appel, LJ, The Verdict From ALLHAT Thiazide Diuretics Are the Preferred Initial Therapy for Hypertension (Editorial). JAMA
2002;288:3039-3042
Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design
and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. The Pharmacogenomics Journal 2002;
2:309–317.
Barzilay JI, Cutler JA, Davis BR. Antihypertensive medications and risk of diabetes mellitus. Current Opinion in Nephrology and
Hypertension 2007; 16:256-260.
Barzilay JI, Cutler JA, Pressel SL, Davis BR. Metabolic Consequences of Thiazide Diuretics for Hypertension. The latest from a
post-hoc analysis of the ALLHAT Trial. Review of Endocrinology 2007; 1:56-57.
Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS, for the ALLHAT Collaborative
Research Group. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid- Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2001; 24:654-658.
Barzilay JI, Davis BR, Bettencourt J, Margolis KL, Goff DC, Black H, Habib G, Ellsworth A, Force RW, Wiegmann T, Ciocon JO,
Basile JN, for the ALLHAT Collaborative Research Group. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the
treatment of hypertension in older adults with and without glucose disorders: A report from the ALLHAT study. J Clin Hypertens
2004; 6:116-125.
Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, for the ALLHAT
Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to
receive 3 different classes of antihypertensive treatment. Arch Intern Med 2006; 166:2191-2201.
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C,
Papademetriou V, Probstfield J, Wright JT, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, for the ALLHAT
Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4:393-404.
Cutler JA, Davis BR, Wright JT, Furberg CD. Rationale and Design for the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT). In: Black HR, ed. Clinical Trials in Hypertension New York, NY: Marcel Dekker; 2001: 531586.
Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, Stokes JD, for the ALLHAT Collaborative Research Group.
Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients
randomly assigned to doxazosin or chlorthalidone: Further analyses from the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial. Ann Intern Med 2002; 137:313-320.
Davis BR, Arnett DK, Boerwinkle E, Ford CE, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH.Antihypertensive therapy, the
alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: The Genetics of HypertensionAssociated Treatment Study. The Pharmacogenomics Journal 2007; 7:112-122.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 2
Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman
MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM, for the ALLHAT Research Group. Rationale and
design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342360.
Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P. ALLHAT: Setting the record straight. Ann Intern Med 2004; 141:39-46.
Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M,
Ellsworth A, Golden J, Colon P, Crow R, for the ALLHAT Collaborative Research Group. The role of diuretics in the prevention of
heart failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Circulation 2006;
113:2201-2210.
Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR, for the ALLHAT
Collaborative Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart
failure validation study: Diagnosis and prognosis. Am Heart J 2007; 153:42-53.
Furberg CD, Cutler JA, Davis BR. Status of alpha-blocker therapy in the treatment of hypertension: Findings of ALLHAT. Harrison’s
Online (http://harrisonsonline.com/server-java/Arknoid/am ed/harrisons/ex_editorials/edl2856_p01.html) September 19, 2001.
Geraci, TS, Geraci, SA, What ALLHAT Tells Us About Treating High-Risk Patients With Hypertension and Hyperlipidemia. (Journal
of Cardiovascular Nursing 2003;18(5):389-395)
Grimm RH, Margolis KL, Papademetriou V, Cushman WC, Ford CE, Bettencourt J, Alderman MH, Basile JN, Black HR, DeQuattro
V, Echfeldt J, Hawkins CM, Proschan M, for the ALLHAT Collaborative Research Group. Baseline characteristics of the participants
in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37:19-27.
Kumar A, Wright JT, Haywood LJ. First results from ALLHAT: Implications for management of urban hypertensives. ABC Digest of
Urban Cardiology 2001; 8: 21-24.
Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart
R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZA, Proschan MA, Thadani U, Whelton PK, Wright JT; for the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Clinical events in high-risk
hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 2006;48:374-384.
Lusk CM, Bettencourt J, Carroll L, Egan D, Ford CE, Kingry C, Johnason J, Sullivan S, Nwachuku C, Probstfield JL. The ALLHAT
Adherence Survival Kit. Applied Clinical Trials 2004; 13:40-48.
Maitland-van der Zee AH, Boerwinkle E, Arnett DK, Davis BR, Leiendecker-Foster C, Miller MB, Klungel OH, Ford CE, Eckfeldt JH.
Absence of an interaction between the angiotensin converting enzyme insertion-deletion polymorphism and pravastatin on
cardiovascular disease in high-risk hypertensive patients: The Genetics of Hypertension-Associated Treatment (GenHAT)
Study. Am Heart J 2007; 153:54-58
Margolis KL, Piller LB, Ford CE, Henriquez MA, Cushman WC, Einhorn PT, Colon PJ Sr, Vidt DG, Christian R, Wong ND, Wright JT
Jr, Goff DC Jr, and ALLHAT Collaborative Research Group. Blood pressure control in Hispanics in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial. Hypertension 2007; In Press.
Neaton, JD, Kuller, LH. Diuretics Are Color Blind. (JAMA 2005;293:1663-1666)
Papademetriou V, Piller LB, Ford CE, Gordon D, Hartney TJ, Geraci TS, Reison E, Sumner BM, Wong ND, Nwachuku C, Narayan
P, Haywood LJ, Habib G, for the ALLHAT Collaborative Research Group. Characteristics and lipid distribution of a large, high-risk,
hypertensive population: The lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT). J Clin Hypertens 2003; 5:377-385.
Pasternak, RC, The ALLHAT Lipid Lowering Trial—Less Is Less (Editorial).Richard C. Pasternak. (JAMA 2002;288:3042-3044
Piller LB, Davis BR, Cutler JA, Cushman WC, Wright JT, Jr, Williamson JD, Leenen FHH, Einhorn PT, Randall OS, Golden JS,
Haywood LJ, for the ALLHAT Collaborative Research Group. Validation of Heart Failure Events in the Antihypertensive and Lipid
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Current
Controlled Trials in Cardiovascular Medicine 2002; 3:10-18.
Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL, for the ALLHAT Collaborative Research
Group. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: A report
from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2006; 8:649656.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 3
Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H, for the ALLHAT
Research Group. Participant Recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Controlled Clinical Trials 2001; 22:674-686.
Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM,
Nwachuku C, Furberg CD, for the ALLHAT Collaborative Research Group. Operational aspects of terminating the doxazosin arm of
the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Controlled Clinical Trials 2001; 22:2941.
Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R, Oparil S, for the ALLHAT Research Group. ALLHAT and calcium
channel blockers. Am J Hypertens 1997;10:142-143.
Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C, for the
ALLHAT Collaborative Research Group. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its
association with cardiovascular disease. A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
TrialArch Intern Med 2004; 164:969-976.
Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr, Whelton P, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin
S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, for the ALLHAT Collaborative
Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Annals
of Internal Medicine 2006; 144:172-180.
Whelton PK, Williamson JD, Louis GT, Davis BR, Cutler JA, for the ALLHAT Research Group. Experimental approaches to
determining the choice of first step therapy for patients with hypertension. Clin Exp Hypertens 1996;18:569-579.
Wright JT, Jr, Cushman WC, Davis BR, Barzilay J, Colon P, Egan D, Lucente T, Nwachuku C, Pressel S, Leenen FHH, Frolkis J,
Letterer R, Walsh S, Tobin JN, Deger GE, for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT): Clinical center recruitment experience. Controlled Clinical Trials 2001; 22:659-673.
Wright JT, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FHH, Margolis KL, Papademetriou V,
Probstfield JL, Whelton PK, Habib GB, for the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and
nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293:1595-1608.
ALLHAT Abstracts and Presentations
Listings are in ascending chronological order; through 2005.
Davis B, for the ALLHAT Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial: Design
features. Presented at 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April-May 1995. Control Clin Trials
1995;16(Suppl 3):475.
Davis B, for the ALLHAT Research Group. Workshop III - Operational perspectives in the conduct of large multicenter clinical trials.
Presented at the 16th Annual Meeting of the Society for Clinical Trials; Seattle, WA; April-May, 1995. Control Clin Trials
1995;16(Suppl 3):14.
Egan D, Pressel S, Davis B, on behalf of the ALLHAT Research Group. Recruitment success by type of site in the Antihypertensive
and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Vanguard. Presented at the 16th Annual Meeting of the
Society for Clinical Trials; Seattle, WA; April-May 1995. Control Clin Trials 1995;16(Suppl 3):106.
Pressel S, Egan D, Ford C, Walsh S, Miertechin N, on behalf of the ALLHAT Research Group. Selection of clinical sites for the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Presented at 16th Annual Meeting of the Society for
Clinical Trials; Seattle, WA; April-May, 1995. Control Clin Trials 1995;16(Suppl 3):106.
Cushman WC, for the ALLHAT Research Group. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) - Design and initial characteristics. Presented at the 11th Scientific meeting of the lnter-American Society of
Hypertension; Montréal, Quebec; June, 1995. Hypertension 1995;25:1356.
Grimm RH, Jr, for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT): Design and early baseline results. Presented at the 11th Asian-Pacific Congress of Cardiology; Bali, Indonesia;
September, 1995.)
Cushman WC. Design and Aims of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Presented at the Panhellenic Congress on Arterial Hypertension; Greece; March, 1996.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 4
Cutler J, Furberg C, Temple R, DeMets D. ALLHAT Invited Presentation - "Equal Risk for Equal Pressure?” Presented at the
Society for Clinical Trials Plenary Session; Pittsburgh, PA; May, 1996.
Grimm RH, Jr, Davis B, Whelton P, Pressel S, for the ALLHAT Research Group.The Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT): Update on recruitment and baseline
characteristic. Presented at the 11th Scientific Meeting of the American Society of Hypertension: New York, NY; May 15-18, 1996.
Am J Hypertension 1996; 9 (Part II): 26A.
Whelton P. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). International Society of
Hypertension book of abstracts, June 1996.
Whelton P, Cutler J, Davis B, Grimm R, Pressel S, Probstfield J, Ward H, for the ALLHAT Research Group. Patient recruitment
experience in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Presented at the 16th
Scientific Meeting of the International Society of Hypertension; Glasgow, U.K.; June 23-27, 1996. J Hypertension 1996; (Suppl
1):998.
Wright JT, Jr, Cutler JA, Davis BR, Cushman WC, Pressel S, for the ALLHAT Research Group. The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT): Recruitment update and baseline data. Presented at the 11th
International Interdisciplinary Conference on Hypertension in Blacks; New Orleans, LA; July 14-17 1996. Conference abstract
monograph.
Davis B, Proschan M, Ford CE, for the ALLHAT Research Group. Statistical design considerations for a large, simple trial of
antihypertensive and lipid lowering treatments. Presented at the International Biometric Conference; Amsterdam, Netherlands; July
1-5, 1996.
Cushman WC. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Update on Southeastern
Clinical Research. Presented at the 3rd Annual Meeting of the Consortium of Southeastern Hypertension Centers; Research
Triangle Park, NC; August, 1996.
Davis BR, Proschan M, Ford CE, for the ALLHAT Research Group. Statistical issues in a large, simple trial of antihypertensive and
lipid-lowering treatments. Presented at the American Statistical Association Meeting; Chicago, IL; August, 1996.
Whelton P. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Int Soc Hypertens 1996.
Papademetriou \/, Grimm KH, Jr, for the ALLHAT Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT]: Design, recruitment experience and baseline characteristics. Presented at the 4th International
Symposium on Multiple Risk Factors in Cardiovascular Disease; Washington, D.C.: April 23-25, 1997.
Barzilay J, Jordan J, Grimin R, Davis B, Oparil S, and the ALLHAT Investigators. Characteristics of the diabetic cohort in the
ALLHAT study. Presented at the 12th Scientific Meeting of the American Society of Hypertension; San Francisco, CA; May, 1997.
Hypertension 1997;10:86A.
Cutler J. Newer vs. older drugs ± cholesterol lowering: ALLHAT. Presented at the WHO-ISH ColIaboration Annual Meeting and
Clinical Trials Symposium; St. Jean Cap Ferrat, France; May, 1997.
Oparil S. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, ALLHAT. Presented at the 4th
International Conference on Preventive Cardiology Satellite Symposium entitled "Optimal Therapy in the Prevention of CAD";
Montreal, Quebec; June 29-July 3, 1997.
Brown N, Evans SA. A clinical data comparison of African American and Non-African American Participants in the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Presented at the 12th Interdisciplinary Conference on Hypertension in
Blacks; London, England; July, 1997. Ethnicity and Disease 1997;7(Suppl):25.
Davis BR, Sacks F, Alderman M, Thornquist M, DeMets DL. The impact of external events on on-going clinical trials. Presented at
the 2nd Joint Meeting of the Society of Clinical Trials/International Society of Clinical Biostatistics; Boston, MA; July, 1997.
Davis BR, Hawkins CM, Cutler JA, Payne G, Ford CE, Pressel S, Gordon D, Nwachuku C, Wright J, Cushman W, Grimm R for the
ALLHAT Research Group.ALLHAT: The largest clinical trial in hypertension ever undertaken. Presented by BR Davis at the 6th
International Symposium on Hypertension in the Community: Screening, Investigation, and Therapy, February 8-11, 1998, Geneva,
Switzerland.
Cushman WC, Black HR, Probstfield JL, Holland JJ, Hamilton BP, Margolis K, Nwachuku CE, Payne GH, Ford CE for the ALLHAT
Research Group. Blood pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). Presented by WC Cushman at the 13th Scientific Meeting of the American Society of Hypertension, May 13-16, 1998,
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 5
New York, NY. Am J Hypertension 1998; 11:17A.
Nwachuku CE, Probstfield JL, Ford CE, Payne GH, Grimm RH for the ALLHAT Research Group. Visit (Vad) and medication (Mad)
adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Effect of age and other
factors. Presented by CE Ford at the 13th Scientific Meeting of the American Society of Hypertension, May 13-16, 1998, New York,
NY. Am J Hypertension 1998; 11(Suppl 1):82A.
Grimm, RH. Regional differences in attainment of goal blood pressure (BP) amongst United States (US) treated hypertensives in
ALLHAT. Presented by at the 17th Scientific Meeting of the International Society of Hypertension, Amsterdam, Netherlands, June 611, 1998.
Margolis KL, Cushman WC, Wright JT, Grimm RH, Ford CE, Cutler JA for the ALLHAT Research Group. Racial differences in blood
pressure control in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Presented by KL Margolis at
the 22nd Annual Meeting of the Society for General Internal Medicine, San Francisco, California, April 30, 1999.
Lusk CM, Egan D, Carroll L, Kingry C, Johnson JM, Sullivan S, Probstfield J for the Antihypertensive and Lipid- Lowering Treatment
to Prevent Heart Attack Trial. ALLHAT Adherence Survival Kit. Presented by CM Lusk at the 20th January 24, 2003 Annual Meeting
of the Society for Clinical Trials, Anaheim, CA, May 3, 1999. Controlled Clinical Trials 1999; 20(2S):38S.
Haywood LJ, Crow R, Ford C, for the ALLHAT Research Group. Atrial fibrillation in the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT) clinical trial at baseline. Presented by LJ Haywood at the 14th International
Interdisciplinary Conference on Hypertension in Blacks, Toronto, Ontario, Canada, July 10-14, 1999.) Ethnicity and Disease 1999;
9:293.
Bettencourt J, Ford CE. Differences in adherence patterns of ALLHAT participants. Presented by J Bettencourt at the 21st Annual
Meeting of the Society for Clinical Trials, Toronto, Canada, April 16-19, 2000. Controlled Clinical Trials 2000; 21:105S-106S.
Colon PJ, Wright JT, Ford CE, Cuttler JA, for the ALLHAT Collaborative Research Group. Cardiovascular disease rates in Hispanic
and Caribbean hypertensives receiving doxazosin and chlorthalidone in the ALLHAT. Presented by PJ Colon at the Joint Meeting of
the International Society for Hypertension in Blacks and the 15th Annual Interdisciplinary Conference on Hypertension and Related
Risk Factors in Ethnic Populations, July 15-18, 2000, Las Croabas, Puerto Rico. Ethnicity and Disease 2000; 10:315-316.
Margolis K, Piller L, Lewis C, Goff D, Cushman W, Wright J, Colon P, Ford C. Blood pressure control in Hispanic participants in
ALLHAT. Presented by K Margolis at the 41st AHA Conference on Cardiovascular Disease Epidemiology and Prevention, San
Antonio, Texas, March 2, 2001. Circulation 2001; 103:1348.
Pressel S. Practical Issues in Conducting Multicenter Clinical Trials. Presented at the 22nd Annual Meeting of the Society for
Clinical Trials, May 20-23, 2001, Denver, Colorado. Controlled Clinical Trials 2001; 22:5S.
Ford C. Conducting clinical trials in private practices: What works and what doesn’t. Presented at the 22nd Annual Meeting of the
Society for Clinical Trials, May 20-23, 2001, Denver, Colorado. Controlled Clinical Trials 2001; 22:17S.
Davis BR. Closeout Procedures for Clinical Trials. Presented at the 22nd Annual Meeting of the Society for Clinical Trials, May 2023, 2001, Denver, Colorado.) Controlled Clinical Trials 2001; 22:22S.
Pressel S, Davis BR, Babiak-Vazquez A, deLeon B, Bettencourt J, Nwachuku C. Follow-up specialist in the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Presented by S. Pressel at the 23rd Annual Meeting of the
Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia. Controlled Clinical Trials 2002; 23:48S.
Davis BR, Pressel S, Ford C, Piller L, Bettencourt J, Simpson LM, deLeon B, Dunn K. The ALLHAT Clinical Trials Center –
Expected and unexpected challenges. Presented by B.R. Davis at the 23rd Annual Meeting of the Society for Clinical Trials, May
12-15, 2002, Arlington, Virginia. Controlled Clinical
Trials 2002; 23:56S.
Pressel S, Davis B, Ford C, Bettencourt J, deLeon B, Piller LB, Simpson LM, Einhorn P, Furberg C, Geraci T, Margolis K, Rahman
M, Juratovac A, Feldman S, Kingry C. Closeout procedures in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT). Presented by S. Pressel at the 23rd Annual Meeting of the Society for Clinical Trials, May 12- 15, 2002,
Arlington, Virginia. Controlled Clinical Trials 2002; 23:57S.
Simpson LM, Pressel S, Piller LB, Bettencourt J, deLeon B, Davis B. Ascertainment of vital status using outside databases in
ALLHAT. Presented by LM Simpson at the 23rd Annual Meeting of the Society for Clinical Trials, May 12- 15, 2002, Arlington,
Virginia. Controlled Clinical Trials 2002; 23:76S.
Piller LB, Simpson LM, Davis BR, Pressel S, deLeon B. The review of event reports in ALLHAT.
Presented by L. Piller at the 23rd Annual Meeting of the Society for Clinical Trials, May 12-15, 2002, Arlington, Virginia. Controlled
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 6
Clinical Trials 2002; 23:77S.
Cushman W, Ford CE, Cutler JA, Margolis KL, Davis BR, Bettencourt J, Grimm RH. Blood pressure control in the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Presented by W. Cushman at the 75th Annual Scientific
Sessions of the American Heart Association, November 17-20, 2002, Chicago, Illinois.
Salive ME, ALLHAT results and future directions for hypertension research. (Presented at the American College of Preventive
Medicine Meeting, February 22, 2003, San Diego, California.)
Wright J, AHT Results. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.)
Haywood J, LLT Results. (Presented at the Association of Black Cardiologist Meeting, March 30, 2003, Chicago, Illinois.))
Williamson J, ALLHAT: Results and implications in older ALLHAT patients. (Presented at the Society of Geriatric Cardiology
Meeting, March 31, 2003, Chicago, Illinois.)
Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group. Cardiovascular disease (CVD)
outcomes in hypertensive patients with impaired renal function. (Presented by M. Rahman at the National Kidney Foundation 2003
Clinical Meetings, April 2-6, 2003, Dallas, Texas.)
Rahman M, Cutler J, Davis B, Pressel S, Whelton P, for the ALLHAT Collaborative Research Group. Renal outcomes in
hypertensive patients with impaired renal function. (Presented by M. Rahman at the National Kidney Foundation 2003 Clinical
Meetings, April 2-6, 2003, Dallas, Texas.)
Ford CE, Margolis KL, Piller L, Cushman WC, Wright JT, Colon PJ, for the ALLHAT Collaborative Research Group. Blood pressure
control in Hispanics in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by
CE Ford at the 15th Scientific Meeting of the Inter-American Society of Hypertension, April 27-30, 2003, San Antonio, Texas.)
Oparil S, Clinical Implications of ALLHAT. (Presented at the 15th Scientific Meeting of the Inter-American Society of Hypertension,
April 27-30, 2003, San Antonio, Texas.)
Cutler J, Barrett S, The ANBP2 and ALLHAT. (Presented at the American Academy of Physician Assistants Meeting, May 26, 2003,
New Orleans, Louisiana.)
Leenen, F, ALLHAT Implications for hypertension in the elderly (Presented at the Canadian Geriatrics Society Annual Meeting, May
30-31, 2003, Ottawa, Canada.)
Alderman M, ALLHAT (Presented at the European Society of Hypertension Meeting, June 13-15 (14), 2003, Milan, Italy.)
Cushman WC, for the ALLHAT Collaborative Research Group. Results of the ALLHAT trial: Antihypertensive trial results by baseline
diabetic & fasting glucose status (Presented at the American Diabetes Association Scientific Sessions, June 13-17 [15th], 2003,
New Orleans, Louisiana.)
Cushman W, ALLHAT vs. ANBP2. (Presented at the Southern Medical Association 7th Annual Conference on Hypertension, June
27-29 (28), 2003, Myrtle Beach, South Carolina.)
Wright J, Subgroup analysis of blacks and diabetics. (Presented at the National Medical Association Meeting, August 2-7, 2003,
Philadelphia, Pennsylvania.)
Probstfield J, ALLHAT and JNC 7. (Presented at the European Society of Cardiology Meeting, August 30 - September 3, 2003,
Vienna, Austria.)
Furberg C, ALLHAT Update. (Presented at Danish Society of Hypertension Meeting, September 25, 2003, Copenhagen, Denmark.)
Wright J. Report from ALLHAT. (Presented at AHA Conference on Cardiovascular Science & Healthcare Disparities: The Minority
Health Summit 2003, October 3, 2003, Atlanta, Georgia.)
Rahman M, Cardiovascular disease and renal disease outcomes in hypertensive patients with various levels of baseline renal
function. (Presented at the American Association of Family Practitioners Meeting, October 4, 2003, New Orleans, Louisiana.)
Hassman J, Effects of ACE inhibitor and calcium channel blocker compared with diuretic in high-risk hypertensive person: Further
results from ALLHAT (Presented at the American Osteopathic Association American College of Osteopathic Family Physicians
Meeting, October 14, 2003, New Orleans, Louisiana.)
Cushman W, Metabolic syndrome & hypertension: ALLHAT – What ALLHAT did? (Presented at the Consortium for Southeastern
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 7
Hypertension Control Meeting, October 16-18, 2003, Coral Gables, Florida.)
Cushman W, Results from ALLHAT. (Presented to the Texas Chapter of the American Society of Hypertension, October 18, 2003,
Houston, Texas.)
Leenen F, What have we learned from ALLHAT? (Presented at Canadian Cardiovascular Congress Meeting, October 25-29 (26),
2003, Toronto, Canada.
Davis BR, Hypertension treatment and diabetes. (Presented at the Chilean Society of Internal Medicine Meeting, October 28-29,
2003, Santiago, Chile.)
Davis BR, First step therapy for hypertension - ALLHAT. (Presented at the Chilean Society of Internal Medicine Meeting, October
28-29, 2003, Santiago, Chile.)
Davis BR, Heart failure, LVH, hypertension and treatment. (Presented at the Chilean Society of Internal Medicine Meeting, October
28-29, 2003, Santiago, Chile.)
Furberg C, ALLHAT: The key findings. (Presented at the 76th Annual Scientific Sessions of the American Heart Association,
November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII Recommendations.)
Probstfield JL, ALLHAT results for subgroups and secondary outcomes (Presented at the 76th Annual Scientific Sessions of the
American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNC-VII
Recommendations.)
Whelton PK, After NHANES, ALLHAT and JNC-VII: How can we implement the findings? (Presented at the 76th Annual Scientific
Sessions of the American Heart Association, November 9-12, 2003, Orlando, Florida. Special Session I: ALLHAT Results and JNCVII Recommendations.)
Haywood LJ, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. Atrial fibrillation at baseline and during follow-up in
ALLHAT. Abstract: Circulation 2003; 108(Suppl IV):IV-371. (Presented by C. Ford at the 76th Annual Scientific Sessions of the
American Heart Association, November 9-12, 2003, Orlando, Florida.)
Einhorn P, Davis B, Piller L, deLeon B, Simpson L, Kostis J, Levy D, Massie B, Nwachuku C, Black H, Cushman W, for the ALLHAT
Collaborative Research Group. Review of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT): ALLHAT Heart Failure Validation StudyAbstract: Circulation 2003; 108(Suppl IV):IV-399. (Presented
by Paula Einhorn at the 76th Annual Scientific Sessions of the American Heart Association, November 9-12, 2003, Orlando,
Florida.)
Rahman M, Incidence of end stage renal disease (ESRD) and cardiovascular disease (CVD) in high risk hypertensive patients with
reduced glomerular filtration rate (GFR). (Presented at the American Society of Nephrology Meeting, November 16, 2003, San
Diego, California.)
Cutler J, ALLHAT: Main results and clinical implications. (Presented at the American Society of Health-System Pharmacists
Meeting, December 9, 2003, New Orleans, Louisiana.)
Heidenreich P, ALLHAT: Cost-effectiveness analysis and societal implications. (Presented at the American Society of HealthSystem Pharmacists Meeting, December 9, 2003, New Orleans, Louisiana.)
Oparil S, Stroke results in ALLHAT. (Presented at the 29th Annual International Stroke Conference, February 5-7, 2004, San Diego,
California.)
Alderman M, New data from ALLHAT. (Presented at the International Society of Hypertension Meeting, February 15-17, 2004, Sao
Paulo, SP, Brazil.)
Furberg C, ALLHAT subgroups – Diabetes, race & renal. (Presented at the American College of Cardiology Meeting, Plenary
Session, March 8, 2004, New Orleans, Louisiana.)
Barzilay JI, Pressel S, Davis BR, Margolis KL, Cutler J, Ong ST, Basile J, Sadler LS, Summerson J, Whelton PK. Risk and impact of
incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: A
report from the ALLHAT trial. Abstract: Am J Hypertension 2004; 17:S1. (Presented by Joshua Barzilay at the 19th Annual Meeting
of the American Society of Hypertension, May 18-22, 2004, New York, NY.)
Cushman WC, Ford CE, Einhorn P, Wright JT, Preston RA, Davis BR, Basile JN. Blood pressure control by randomized drug group
in ALLHAT. Abstract: Am J Hypertension 2004; 17:S30. (Presented by Bill Cushman at the 19th Annual Meeting of the American
Society of Hypertension, May 18-22, 2004, New York, NY.)
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 8
Cutler JA, Piller LB, Pressel S, Graumlich JF, Hamilton BP, Parish DC, Qureshi N, Randall OS, Davis BR. Results of monotherapy
in ALLHAT: On-treatment analyses. Abstract: Am J Hypertension 2004; 17:S30-31. (Presented by Jeff Cutler at the 19th Annual
Meeting of the American Society of Hypertension, May 18-22, 2004, New York, NY.)
Davis B, Diuretics versus ACE inhibitors and calcium channel blockers in the preventing heart failure. (Invited talk. Presented at the
19th Annual Meeting of the American Society of Hypertension, May 22, 2004, New York, NY.)
Black H, Diuretics versus ACE inhibitors and calcium channel blockers in the diabetic patient (Invited talk. Presented at the 19th
Annual Meeting of the American Society of Hypertension, May 22, 2004, New York, NY.)
Haywood J, Ford CE, Crow RS, Davis BR, Einhorn PT, Williard A, Massie B. Atrial Fibrillation in ALLHAT. Abstract: Ethnicity and
Disease 2004. (Presented by Julian Haywood at the International Society on Hypertension in Blacks Meeting, June 13-16, 2004,
Detroit, Michigan.)
Cutler J, Results of monotherapy in ALLHAT: On-treatment analyses Abstract: J of Hypertension 2004; 22(Suppl 2) (Presented at
the European Society of Hypertension Meeting, June 13-17, 2004, Paris, France.)
Grimm R, Did type of prior antihypertensive therapy influence the heart failure results in ALLHAT? Abstract: J of Hypertension
2004; 22(Suppl 2):S151. (Presented at the European Society of Hypertension Meeting, June 13-17, 2004, Paris, France.)
Williamson J, ALLHAT: Results and implications for older patients (Presented at the American Society of Hypertension Carolinas/
Georgia Chapter Meeting, June 26, 2004, Hilton Head, South Carolina.)
Davis B. Heart failure results in ALLHAT (Presented at the European Society of Cardiology Scientific Sessions, August 28September 1, 2004 [8/29], Munich, Germany.)
Kostis J, Preserved and impaired left ventricular systolic function in ALLHAT (Presented at the European Society of Cardiology
Scientific Sessions, August 28-September 1, 2004 [9/1], Munich, Germany.)
Thadani T. Clinical outcomes in ALLHAT antihypertensive trial participants with type 2 diabetes, impaired fasting glucose, and
normoglycemia. (Presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.)
Leenen F, Heart failure results in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. (Poster
presented at the Canadian Cardiovascular Congress, October 23-27, 2004, Calgary, Canada.)
Einhorn P, The ALLHAT HF Validation Study: Clinical presentation of hospitalized HF events and subsequent mortality rates.
(Poster presentation at 77th Annual Scientific Sessions of the American Heart Association, November 7-10, 2004, New Orleans,
Louisiana.)
Davis B, Clinical outcomes in ALLHAT antihypertensive trial participants with cardiovascular dysmetabolic syndrome (Presented at
77th Annual Scientific Sessions of the American Heart Association, November 7-10, 2004, New Orleans, Louisiana.)
Whelton PK, Barzilay J, Cushman WC, Davis BR, Liamathi E, Kostis JB, Leenen FHH, Louis GT, Margolis K, Mathis DE, Moloo J,
Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U. Clinical outcomes in ALLHAT antihypertensive trial
participants with type 2 diabetes, impaired fasting glucose, and normoglycemia. Abstract: Southern Medical Journal 2004; 97(Supp
1):6. (Oral presentation by Paul Whelton at the 98th Annual Scientific Assembly of the Southern Medical Association, November 1113, 2004, New Orleans, Louisiana.)
Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. Outcomes in high-risk hypertensives randomized to CCB vs,
ACE inhibitor in ALLHAT. (Presented by Frans Leenen at American Society of Hypertension, May 14-18, 2005, San Francisco, CA.)
Davis B, Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive
persons: The GenHAT Study. (Presented by Barry Davis at American Society of Hypertension, May 14-18, 2005, San Francisco,
CA.)
Piller L, Ford C, Davis B, Nwachuku C, Black H, Oparil S, Gappy S, Retta T, Probstfield J. Angioedema in the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by Linda Piller at 20th Annual Scientific Meeting of the
American Society of Hypertension, May 14-18 [16], 2005, San Francisco, CA.)
Pressel S, Davis B, Bartholomew LK, Cushman W, Whelton P, Nwachuku C. Disseminating clinical trial results: Case study from the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Abstract: Clinical Trials 2005; 2(Suppl
1):S37. (Presented by Sara Pressel at the 26th Annual Meeting of the Society for Clinical Trials, May 22-25, 2005, Portland,
Oregon.)
Davis BR, Grimm R, Piller L, Cutler J, Margolis K, Barzilay J, Dart R, Graumlich J, Murden R, Randall O, Sawyer K, for the ALLHAT
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 9
Collaborative Research Group. Use of case-only analysis in clinical trials – rational and example Abstract: Clinical Trials 2005;
2(Suppl 1):S33. (Presented by Barry Davis at the 26th Annual Meeting of the Society for Clinical Trials, May 22-25[24th], 2005,
Portland, Oregon.)
Davis B, Cardiovascular and renal outcomes in patients with diabetes (Presented at the Blood Pressure Lowering Treatment
Trialists’ Collaboration Symposium, June 16, 2005, Milan, Italy.)
Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. Cardiovascular outcomes in hypertensives with CHD
randomized to amlodipine versus lisinopril in ALLHAT. (Presented by William Cushman at European Society of Hypertension
Scientific Sessions, June 17-21, 2005, Milan, Italy.)
Leenen F, Nwachuku MA, Cushman W, Black H, Simpson L, Davis B. Outcomes in high-risk hypertensives randomized to CCB vs,
ACE inhibitor in ALLHAT. (Presented by William Cushman at European Society of Hypertension Scientific Sessions, June 17-21,
2005, Milan, Italy.)
Davis B, Absence of interaction between ADD1 Gly460Trp and antihypertensive drug on cardiovascular risk in hypertensive
persons: The GenHAT Study (European Society of Hypertension, June 17-21, 2005, Milan, Italy.)
Black H, Davis B. Clinical outcomes in participants with metabolic syndrome in ALLHAT (Presented by Henry Black at European
Society of Hypertension, June 17-21[19], 2005, Milan, Italy.)
Wright JT Jr, Davis BR, Black HR, for ALLHAT Collaborative Research Group. Clinical outcomes by race in non-diabetic participants
with cardiovascular dysmetabolic syndrome in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(Oral presentation by Jackson Wright at ISHIB, July 15-19, 2005, San Juan, Puerto Rico.)
Wright J, Race (National Medical Association, July 23-28, 2005, New York, NY)
Wright J, Clinical outcomes by race in non-diabetic participants with cardiovascular metabolic syndrome in the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial (National Medical Association, July 23-28, 2005, New York, NY)
Alderman MH, Piller LB, Ford CE, Davis BR, Einhorn P, Cushman W, Calhoun D, Eckfeldt J, Franklin S, Furberg C, Ong S, Oparil
S, Papademetriou V, Probstfield J. The occurrence and clinical impact of hypo- and hyperkalemia in ALLHAT. (Presented by Jeff
Probstfield at the European Society of Cardiology Congress 2005, September 3-7[7th], 2005, Stockholm, Sweden.)
Oparil S, Davis B, Nwachuku C, Pressel S, Alderman M, Calhoun D, Cushman W, Cutler C, Ellsworth A, Fendley H, Franklin S,
Habib G, Leenen F, Probstfield J, Sastrasinh S, for the ALLHAT Research Group. Stroke results: The Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). (Presented by Susan Oparil at the 78th Annual Scientific Sessions of
the American Heart Association, November 13-16 [14], 2005, Dallas, Texas.)
Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) Publications
Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moye LA, Hill
MD, Wojner AW, CLOTBUST Investigators. Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke. N Engl J Med.
2004 Nov 18;351(21):2170-2178.
Choi JY, Pary JK, Alexandrov AV, Molina CA, Garami Z, Malkoff MD, Rubiera M, Shaltoni HM, Moye LA, Grotta JC. Does ClinicalCT 'Mismatch' Predict Early Response to Treatment with Recombinant Tissue Plasminogen Activator? Cerebrovasc Dis. 2006 Aug
4;22(5-6):384-388.
Gonzales NR, Albright KC, Noser EA, Khaja AM, Shaltoni HM, Romman A, Zimbaldi N, Baraniuk MS, Moye LA, Grotta JC. "Mild
Stroke" should Not Exclude Patients from Thrombolytic Therapy. Stroke. 2006 Feb;37(2):621.
Sugg RM, Gonzales NR, Matherne DE, Ribo M, Shaltoni HM, Baraniuk S, Noser EA, Grotta JC. Myocardial Injury in Patients with
Intracerebral Hemorrhage Treated with Recombinant Factor VIIa. Neurology. 2006 Sep 26;67(6):1053-1055.
Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, Mikulik R, Garami Z, Shaw SG, Matherne DE, Moye LA,
Alexandrov AV, Grotta JC. Argatroban tPA Stroke Study: Study Design and Results in the First Treated Cohort. Arch Neurol. 2006
Aug;63(8):1057-1062.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 10
Cholesterol and Recurrent Events (CARE ) Publications
Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project-a combined analysis of three
large-scale randomized trials: Long-term Intervention with pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent
Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76:899-905.
Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the
CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial
infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial.
Circulation 1998;98:2513-2519.
Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JMO, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. Predictors of late
development of heart failure in stable survivors of myocardial infarction: The CARE study.J Am Coll Cardiol 2003; 42:1446-53.
Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer
MA, Braunwald E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in
the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-689.
Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald
E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE)
trial. J Am Coll Cardiol 1998;32:140-6.
Moye LA, Davis BR, Sacks F, Cole T, Brown L, Hawkins CM. Decision rules for predicting future lipid values in screening for a
cholesterol reduction clinical trial. Control Clin Trials 1996;17:536-546.
Pfeffer MA, Sacks FM, Moye LA, East C, Goldman S, Nash DT, Rouleau JR, Rouleau JL, Sussex BA, Theroux P, Vanden Belt RJ,
Braunwald E. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol and Recurrent Events. J Am
Coll Cardiol 1999;33:125-130.
Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, et al.
Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol
1995;76:98C-106C.
Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM,
Braunwald E. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events
(CARE) Study. Circulation 1999;99:216-223.
Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of
coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL
concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
Circulation 1998;97:1446-52.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR,
Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
Sacks FM, Rouleau JL, Moye LA, Pfeffer MA, Warnica JW, Arnold JM, Nash DT, Brown LE, Sestier F, Rutherford J, et al. Baseline
characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum
cholesterol levels. Am J Cardiol 1995;75:621-623.
Sacks FM, Pfeffer MA, Moye' L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E. Rationale and design of a secondary
prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events
trial [Published erratum appears in Am J Cardiol 1992;69:574]. Am J Cardiol 1991;68:1436-1446.
Wilt TJ, Davis BR, Meyers DG, Rouleau JL, Sacks FM. Prevalence and correlates of symptomatic peripheral atherosclerosis in
individuals with coronary heart disease and cholesterol levels less than 240 mg/dl: baseline results from the Cholesterol and
Recurrent Events (CARE) Study. Angiology 1996;47:533-541.
NITRODUR Publications
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 11
Mahmarian JJ, Moye LA, Chinoy DA, Sequeira RF, Habib GB, Henry WJ, Jain A, Chaitman BR, Weng CS, Morales-Ballejo H, Pratt
CM1.Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial
infarction: results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 1998;97:2017-2024.
Mahmarian JJ, Moye LA, Nasser GA, Nagueh SF, Bloom MF, Benowitz NL, Verani MS, Byrd WG, Pratt CM. Nicotine patch therapy
in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol 1997;30:125-130.
Pratt CM, Mahmarian JJ, Morales-Ballejo H, Casareto R, Moye LA. Design of a randomized, placebo-controlled multicenter trial on
the long-term effects of intermittent transdermal nitroglycerin on left ventricular remodeling after acute myocardial infarction.
Transdermal Nitroglycerin Investigators Group. Am J Cardiol 1998;81:719-724.
Survival and Ventricular Enlargement (SAVE) Publications
Gorkin L, Follick MJ, Geltman E, Hamm P, Sollano J, Sylvia S, Jacobson K, Jacobson MJ, Cochrane BS, Sussex B, et al. Quality of
life among patients post-myocardial infarction at baseline in the Survival and Ventricular Enlargement (SAVE) trial. Qual Life Res
1994;3:111-119.
Hager WD, Davis BR, Riba A, Moye LA, Wun CC, Rouleau JL, Lamas GA, Pfeffer MA. Absence of a deleterious effect of calcium
channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE
Investigators. Survival and Ventricular Enlargement. Am Heart J 1998;135:406-413.
Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO, et al. N-terminal
proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:19341942.
Hartley LH, Flaker G, Basta L, Menapace F, Goldman S, Davis B, Hamm P, Lamas G, Moye L, Wun CC, et al. Physical working
capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril. Am J Cardiol 1995;76:857-860.
Lamas GA, Mitchell GF, Flaker GC, Smith SC Jr, Gersh BJ, Basta L, Moye L, Braunwald E, Pfeffer MA. Clinical significance of mitral
regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation 1997;96:827-833.
Lamas GA, Flaker GC, Mitchell G, Smith SC Jr, Gersh BJ, Wun CC, Moye L, Rouleau JL, Rutherford JD, Pfeffer MA, et al. Effect of
infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.
Circulation 1995;92:1101-1109.
Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of
cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med 1992;327:241-247.
Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, Gottlieb SS, Lamas GA, Moye LA, Goldhaber SZ, Pfeffer MA. Ventricular
dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
Mitchell GF, Moye LA, Braunwald E, Rouleau JL, Bernstein V, Geltman EM, Flaker GC, Pfeffer MA. Sphygmomanometrically
determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with
impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation 1997;96:4254-4260.
Moye LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, Farnham DJ, Randall OS, Dinh H, Arnold JM, et al. Uniformity of
captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994;15(Suppl.
B):2-8 (discussion 26-30).
Moye LA, Davis BR, Hawkins CM. Analysis of a clinical trial involving a combined mortality and adherence dependent interval
censored endpoint. Stat Med 1992;11:1705-1717.
Moye LA. Central laboratory sampling plans and quality control in clinical trials. Control Clin Trials 1991;12:761-767.
Moye LA, Pfeffer MA, Braunwald E. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial
(SAVE). SAVE Investigators. Am J Cardiol 1991;68:70D-79D.
Pfeffer MA. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993;18(Suppl 1):430-435.
Pfeffer MA, Braunvald Iu, Moye LA, Basta L, Braun Edzh, Kaddi TE, Devis BR, Geltman EM, Goldman S, Fleiker GS, et al. [Effect of
captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival
and hypertrophic studies][Article in Russian]. Kardiologiia 1993;33:14-23.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 12
Pfeffer MA. Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement. Am J Hypertens 1994;7(Suppl):106S111S.
Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect
of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival
and Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
Pfeffer MA, Moye LA, Braunwald E, Basta L, Brown EJ Jr, Cuddy TE, Dagenais GR, Flaker GO, Geltman EM, Gersh BJ, et al.
Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA 1991;266:528-532.
Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, et al. Prognostic
value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24:583591.
Rouleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, Dagenais GR, Sussex B, Arnold JM, Sestier F, et al. Activation
of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993;22:390-398.
Rouleau JL, Moye LA, Pfeffer MA, Arnold JM, Bernstein V, Cuddy TE, Dagenais GR, Geltman EM, Goldman S, Gordon D, et al. A
comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N
Engl J Med 1993;328:779-784.
Rouleau JL, Moye LA, de Champlain J, Klein M, Bichet D, Packer M, Dagenais G, Sussex B, Arnold JM, Sestier F, et al. Activation
of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991;68:80D-86D.
Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, et al. Effects
of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE
Investigators. Circulation 1994;90:1731-1738.
St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, Rouleau J, Parker JO, Arnold MO, Sussex B, Braunwald
E. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of longterm use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997;96:3294-3299.
St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas GA, Klein M, Sussex B, Goldman S, et al.
Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute
myocardial infarction. The protective effects of captopril. Circulation 1994;89:68-75.
Solomon SD, St John Sutton M, Lamas GA, Plappert T, Rouleau JL, Skali H, Moye LA, Braunwald E, Pfeffer MA. Ventricular
Remodeling Does Not Accompany the Development of Heart Failure in Diabetic Patients After Myocardial Infarction.
Steingart RM, Packer M, Hamm P, Coglianese ME, Gersh B, Geltman EM, Sollano J, Katz S, Moye L, Basta LL, et al. Sex
differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med
1991;325:226-230.
Tsevat J, Pfeffer MA, Goldman L, Lee TH. Economic aspects of captopril treatment. Eur Heart J 1997;18:165.
Tsevat J, Duke D, Goldman L, Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH. Cost-effectiveness of captopril therapy after
myocardial infarction. J Am Coll Cardiol 1995;26:914-919.
Urena PE, Lamas GA, Mitchell G, Flaker GC, Smith SC Jr, Wackers FJ, McEwan P, Pfeffer MA. Ejection fraction by radionuclide
ventriculography and contrast left ventriculogram. A tale of two techniques. SAVE Investigators. Survival and Ventricular
Enlargement. J Am Coll Cardiol 1999;33:180-185.
Vantrimpont P, Rouleau JL, Ciampi A, Harel F, de Champlain J, Bichet D, Moye LA, Pfeffer M
Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur
Heart J 1998;19:1552-1563.
Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B, Arnold JM, Moye L, Pfeffer M. Additive beneficial effects of
beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE
Investigators. J Am Coll Cardiol 1997;29:229-236.
Zornoff LAM, Skali H, Pfeffer MA, St John Sutton M, Rouleau JL, Lamas GA, Plappert T, Rouleau JR, Moye LA, Lewis SJ,
Braunwald E, Solomon SD, for the SAVE Investigators. Right Ventricular Dysfunction and Risk of Heart Failure and Mortality After
Myocardial Infarction.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 13
Systolic Hypertension in the Elderly Program (SHEP) Publications
Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, Greenlick MR, Hadley E, Moye L, Perry HM Jr., et al. Impact of
the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.
Arch Intern Med 1994;154:2154-2160.
Applegate WB, Davis BR, Black HR, Smith WM, Miller ST, Burlando AJ. Prevalence of postural hypotension at baseline in the
Systolic Hypertension in the Elderly Program (SHEP) cohort. J Am Geriatr Soc 1991;39:1057-1064.
Bearden D, Allman R, McDonald R, Miller S, Pressel S, Petrovitch H. Age, race, and gender variation in the utilization of coronary
artery bypass surgery and angioplasty in SHEP. SHEP Cooperative Research Group. Systolic Hypertension in the Elderly Program.
J Am Geriatr Soc 1994;42:1143-1149.
Black HR, Unger D, Burlando A, Wright JC, Pressel SL, Allen R, McDonald RH, Surath H. Systolic Hypertension in the Elderly
Program (SHEP). Part 6: Baseline physical examination findings. Hypertension 1991;17(Suppl 2):77-101.
Borhani NO, Applegate WB, Cutler JA, Davis BR, Furberg CD, Lakatos E, Page L, Perry HM, Smith WM, Probstfield JL. Systolic
Hypertension in the Elderly Program (SHEP). Part 1: Rationale and design. Hypertension 1991;17(Suppl 2):2-15.
Brittain E, Palensky J, Blood J, Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample
example from the Systolic Hypertension in the Elderly Program (SHEP). Stat Med 1997;16:681-693.
Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G,
Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older
diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group
[Published erratum appears in JAMA 1997;277:1356]. JAMA 1996;276:1886-1892.
Davis BR, Vogt T, Frost PH, Burlando A, Cohen J, Wilson A, Brass LM, Frishman W, Price T, Stamler J. Risk factors for stroke and
type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research
Group. Stroke 1998;29:1333-1340.
Davis BR, Wittes J, Pressel S, Berge KG, Hawkins CM, Lakatos E, Moye LA, Probstfield JL. Statistical considerations in monitoring
the Systolic Hypertension in the Elderly Program (SHEP). Control Clin Trials 1993;14:350-361.
Di Bari M, Pahor M, Franse LV, Shorr RI, Wan JY, Ferrucci L, Somes GW, Applegate WB. Dementia and disability outcomes in
large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial. Am J Epidemiol
2001;153:72-78.
Franse LV, Pahor M. Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and
cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000;35:1025-1030.
Franse LV, Pahor M. Di Bari M, Shorr RI, Wan JY, Somes GW, Applegate WB. Serum uric acid, diuretic treatment and risk of
cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-1154.
Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP Jr., Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J. Serum
lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation
1996;94:2381-2388.
Frost PH, Davis BR, Burlando AJ, Curb JD, Guthrie GP, Isaacsohn JL, Wassertheil-Smoller S, Wilson AC, Stamler J. Coronary
heart disease risk factors in men and women aged 60 years and older: findings from the Systolic Hypertension in the Elderly
Program. Circulation 1996;94:26-34.
Hall WD, Davis BR, Frost P, Hoffmeier M, O'Brien JE, Pace S, Page L, Schneider KA, Stamler J. Systolic Hypertension in the
Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension 1991;17(Suppl 2):102-122.
Hertert S, Bailey G, Cottinghan V, Carmody S, Egan D, Johnson P, Probstfield J. Community volunteers as recruitment staff in a
clinical trial: the systolic hypertension in the elderly program (SHEP) experience [Published erratum appears in Control Clin Trials
1996;17:271]. Control Clin Trials 1996;17:23-32.
Kostis JB, Lawrence-Nelson J, Ranjan R, Wilson AC, Kostis WJ, Lacy CR, for the Systolic Hypertension in the Elderly (SHEP)
Cooperative Research Group. Association of Increased Pulse Pressure With the Development of Heart Failure in SHEP. Am J
Hypertens 2001;14:798-803.
Kostis JB, Davis BR, Cutler J, Grimm RH Jr., Berge KG, Cohen JD, Lacy CR, Perry HM Jr., Blaufox MD, Wassertheil-Smoller S,
Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 14
drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 1997;278:212-216.
Kostis JB, Berge KG, Davis BR, Hawkins CM, Probstfield J. Effect of atenolol and reserpine on selected events in the systolic
hypertension in the elderly program (SHEP). Am J Hypertens 1995;8:1147-1153.
Kostis JB, Lacy CR, Hall WD, Wilson AC, Borhani NO, Krieger SD, Cosgrove NM. The effect of chlorthalidone on ventricular ectopic
activity in patients with isolated systolic hypertension. The SHEP Study Group. Am J Cardiol 1994;74:464-467.
Kostis JB, Allen R, Berkson DM, Curb JD, Davey J, Grimm RH, Hall WD, Lacy CR, Lee M, Miller S, et al. Correlates of ventricular
ectopic activity in isolated systolic hypertension. SHEP Cooperative Research Group. Am Heart J 1994;127:112-121.
Hall WD, Davis BR, Frost P, Hoffmeier M, O'Brien JE, Pace S, Page L, Schneider KA, Stamler J. Systolic Hypertension in the
Elderly Program (SHEP). Part 7: Baseline laboratory characteristics. Hypertension 1991;17(Suppl 2):II102-II22.
Labarthe DR, Blaufox MD, Smith WM, Lacy CR, Schnaper H, LaBaw F, Mascioli S, Davey J, Lakatos E. Systolic Hypertension in the
Elderly Program (SHEP). Part 5: Baseline blood pressure and pulse rate measurements. Hypertension 1991;17(Suppl 2):II62-II76.
Moye LA, Davis BR, Hawkins CM, Probstfield JL. Conclusions and implications of the systolic hypertension in the elderly program.
Clin Exp Hypertens 1993;15:911-924.
Perry HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, Kuller L, Pressel S, Stamler J, Probstfield JL. Effect of
treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in
the Elderly Program (SHEP). JAMA 2000;284:465-471.
Perry HM, Berge KG, Blaufox MD, Davis BR, Grimm RH, McDonald R, Pressel S, Schron E, Smith WM, Vogt TM. The systolic
hypertension in the elderly program. In: Leonetti G, Cuspidi C, editors. Hypertension in the elderly. Dordrecht, The Netherlands:
Kluwer Academic Press; 1994. p.123-137.
Petrovitch H, Vogt TM, Berge KG, for the SHEP Cooperative Research Group. Isolated systolic hypertension: lowering the risk of
stroke in older patients. Geriatrics 1992;47:30-32, 35-38.
Probstfield JL, Applegate WB, Borhani NO, Curb JD, Cutler JA, Davis BR, Furberg CD, Hawkins CM, Lakatos E, Page LB, et al. The
Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative
Research Group. Clin Exp Hypertens [A] 1989;11:973-989.
Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, Cohen J, Davis BR, Frost P, Smith W, Gonzalez N, Guthrie
GP, Oberman A, Rutan G, Probstfield JL, Stamler J. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on
glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic
Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998;158:741-751.
Schron EB, Wassertheil-Smoller S, Pressel S. Clinical trial participant satisfaction: survey of SHEP enrollees. SHEP Cooperative
Research Group. Systolic Hypertension in the Elderly Program. J Am Geriatr Soc 1997;45:934-938.
SHEP Cooperative Research Group. Implications of the systolic hypertension in the elderly program. Hypertension 1993;21:335343.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic
hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
SHEP Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic
hypertension. J Clin Epidemiol 1988;41:1197-1208.
Vogt TM, Schron E, Pressel S, Wasserthiel-Smoller S, Eddleman EE, Miller S, Stamler J. Systolic Hypertension in the Elderly
Program (SHEP). Part 3: Sociodemographic characteristics. Hypertension 1991;17(Suppl 2):24-34.
Wassertheil-Smoller S, Applegate WB, Berge K, Chang CJ, Davis BR, Grimm R Jr., Kostis J, Pressel S, Schron E. Change in
depression as a precursor of cardiovascular events. SHEP Cooperative Research Group (Systolic Hypertension in the elderly). Arch
Intern Med 1996;156:553-561.
Weiler PG, Camel GH, Chiappini M, Greenlick MR, Hughes GH, Luhr JC, Moye LA, Mungas D, Perron M, Peters MH, et al. Systolic
Hypertension of the Elderly Program (SHEP). Part 9: Behavioral characteristics. Hypertension 1991;17(Suppl 2):152-161.
Wittes J, Davis B, Berge K, Cohen JD, Grimm RH Jr., Hawkins CM, Kuller L. Systolic Hypertension of the Elderly Program (SHEP).
Part 10: Analysis. Hypertension 1991;17(Suppl 2):162-167.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 15
Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J. Blood pressure and decline in kidney function: findings from the
Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol 2002;13:2776-2782.
Trial of Antihypertensive Interventions and Management Publications
Blaufox MD, Lee HB, Davis B, Oberman A, Wassertheil-Smoller S, Langford H. Renin predicts diastolic blood pressure response to
nonpharmacologic and pharmacologic therapy. JAMA 1992;267:1221-1225.
Davis BR, Oberman A, Blaufox MD, Wassertheil-Smoller S, Zimbaldi N, Kirchner K, Wylie-Rosett J, Langford HG. Lack of
effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with
mild hypertension. TAIM Research Group. Trial of Antihypertensive Interventions and Management. Am J Hypertens 1994;7:926932.
Davis BR, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG. Reduction in long-term
antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild
hypertension. Arch Intern Med 1993;153:1773-1782.
Davis BR, Oberman A, Blaufox MD, Wassertheil-Smoller S, Hawkins CM, Cutler JA, Zimbaldi N, Langford HG. Effect of
antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group.
Hypertension 1992;19:393-399.
Davis BR, Blaufox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N.
Trial of antihypertensive interventions and management. Design, methods, and selected baseline results. Controlled Clin Trials
1989;10:11-30.
Langford HG, Davis BR, Blaufox D, Oberman A, Wassertheil-Smoller S, Hawkins M, Zimbaldi N. Effect of drug and diet treatment of
mild hypertension on diastolic blood pressure. The TAIM Research Group. Hypertension 1991;17:210-217.
Langford HG, Rockhold RW, Wassertheil-Smoller S, Oberman A, Davis BR, Blaufox MD. Effect of weight loss on thiazide produced
erectile problems in men. Trans Am Clin Climatol Assoc 1989;101:190-194.
Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins CM. Pharmacologic
and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med 1990;112:89-95.
Wassertheil-Smoller S, Davis BR, Breuer B, Chang CJ, Oberman A, Blaufox MD. Differences in precision of dietary estimates
among different population subgroups. Ann Epidemiol 1993;3:619-628.
Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive
Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild
hypertension. Arch Intern Med 1992;152:131-136.
Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, Hawkins CM, Langford HG. Antihypertensive
therapy’s effect on the quality of life. Cardiology Board Review 1992;9:65-72.
Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management
(TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992;5:37-44.
Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, Hawkins CM, Langford HG. Effect of
antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991;114:613-620.
Wassertheil-Smoller S, Davis BR, Oberman A, Blaufox MD, Langford H, Wylie-Rosett J, Hawkins M, Zimbaldi N. The TAIM study:
sex-race differences in effects of diet and drugs on cardiovascular risk. Cardiovasc Risk Factors 1991;1:427-435.
Wassertheil-Smoller S, Langford HG, Yamori Y, Blaufox MD, Oberman A, Davis B, Nara Y, Wylie-Rosett J, Zimbaldi N. Estimation
of protein intake: comparison of dietary assessment and urinary excretion. J Cardiovasc Pharmacol 1990;16 (Suppl. 8):S28-S31.
Wylie-Rosett J, Wassertheil-Smoller S, Blaufox MD, Davis BR, Langford HG, Oberman A, Jennings S, Hataway H, Stern J, Zimbaldi
N. Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium
intervention. J Am Diet Assoc 1993;93:408-415.
Retinopathy of Prematurity (ROP: CRYO-, LIGHT-) Publications
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 16
Bartholomew PA, Chao J, Evans JL, Hammel AM, Trueb AL, Verness JL, Dobson V, Quinn GE. Acceptance/Use of the Teller acuity
card procedure in the clinic. Am Orthoptic J 1996;46:99-105.
Bremer L, Fellows RR, Palmer EA, Baker JD, Hardy RJ, Tung B, Rogers GL. Strabismus in premature infants in the first year of life.
Arch Ophthalmol 1998; 116:329-333
Cohen KW, Byrne SM. The role of the nurse in assisting with eye examinations on premature infants. Neonatal Network 1989;8:3135.
Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity:
Snellen acuity and structural outcome at 5½ years. Arch Ophthalmol 1996;114:417-424.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. The natural ocular outcome of premature birth and retinopathy:
status at one year. Arch Ophthalmol 1994;112:903-912.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: 3½year outcome--structure and function. Arch Ophthalmol 1993;111:339-344.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: threemonth outcome. Arch Ophthalmol 1990;108:195-204.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: oneyear outcome--structure and function. Arch Ophthalmol 1990;108:1408-1416.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity:
preliminary results. Arch Ophthalmol 1988;106:471-479.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity:
preliminary results. Pediatrics 1988;81:697-706.
Dobson V, Quinn GE, Siatkowski RM, Baker JD, Hardy RJ, Reynolds JD, Trese MT, Tung B, for the Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Agreement between grating acuity at age 1 year and Snellen acuity at age 5.5 years in the preterm
child. Invest Ophthalmol Vis Sci 1999;40:496-503
Dobson V, Quinn GE, Abramov I, Hardy RJ, Tung B, Siatkowski RM, Phelps DL, for the Cryotherapy for Retinopathy of Prematurity
Group. Color vision measured with standard pseudoisochromatic plates at 5½ years in eyes of children from the CRYO-ROP study.
Inv Ophthalmol Vis Sci 1996;37:2467-2474.
Dobson V, Quinn GE, Tung B, Palmer EA, Reynolds JD, for the Cryotherapy for Retinopathy of Prematurity Cooperative Group.
Comparison of recognition and grating acuities in very low birth weight children with and without retinal residua of retinopathy of
prematurity (ROP). Invest Ophthalmol Vis Sci 1995;36:692-702.
Dobson V, Quinn GE, Saunders RA, Spencer R, Davis BR, Risser J, Palmer EA, for the Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Grating visual acuity in eyes with retinal residua of retinopathy of prematurity (ROP). Arch Ophthalmol
1995;113:1172-1177.
Dobson V, Quinn GE, Summers CG, Saunders RA, Phelps DL, Tung B, Palmer EA. Effect of acute-phase retinopathy of
prematurity on grating acuity development in the very low birth weight infant. Invest Ophthalmol Vis Sci 1994;35:4236-4244.
Dobson V, Quinn GE, Biglan AW, Tung B, Flynn JT, Palmer EA. Acuity card assessment of visual function in the cryotherapy for
retinopathy of prematurity trial. Invest Ophthalmol Vis Sci 1990;31:1702-1708.
Evans MS, Wallace PR, Palmer EA. Fundus photography in infants. J Ophthal Photography 1993;15:38-9.
Gilbert WS, Quinn GE, Dobson V, Reynolds J, Hardy RJ, Palmer EA, for the CRYO-ROP Cooperative Group. Partial retinal
detachment at 3 months after threshold retinopathy of prematurity: Long term structural and functional outcome. Arch Ophthalmol
1996;114:1085-1091.
Gilbert WS, Dobson V, Quinn GE, Reynolds J, Tung B, Flynn JT. The correlation of visual function with posterior retinal structure in
severe retinopathy of prematurity. Arch Ophthalmol 1992;110:625-631.
Hardy RJ, Palmer EA, Schaffer DB, Phelps DL, Davis BR, Cooper CJ, for the Multicenter Trial of Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Outcome-based management of retinopathy of prematurity. JAAPOS 1997;1:46-54.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 17
Hardy RJ, Davis BR, Palmer, EA, Tung B. Statistical considerations in the early termination of the multicenter trial of cryotherapy for
retinopathy of prematurity. Control Clin Trials 1991;12:293-303.
Hardy RJ, Good WV, Dobson V, Palmer EA, Tung B, Phelps DL, Shapiro MJ, van Heuven WAJ on behalf of the ETROP
Cooperative Group. The Early Treatment for Retinopathy of Prematurity Clinical Trial: Presentation by Subgroups versus Analysis
within Subgroups. Br J Ophthalmol 2006;90:1341-1342.
Kivlin JD, Biglan AW, Gordon RA, Dobson V, Hardy RA, Palmer EA, Tung B, Gilbert W, Spencer R, Cheng KP, Buckley E, for the
Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Cooperative Group. Early retinal vessel development and iris vessel
dilatation as factors in retinopathy of prematurity. Arch Ophthalmol 1996;114:150-154.
Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B, the Cryotherapy for Retinopathy of Prematurity
Cooperative Group. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991;98:1628-1640.
Palmer EA, Hardy RJ, Mowery R, Davis BR, Tung B, Phelps DL, Schaffer DB, Flynn JT. Operational aspects of early termination of
the multicenter trial of cryotherapy for retinopathy of prematurity. Control Clin Trials 1991;12:277-292.
Phelps DL, Brown DR, Tung B, Cassady G, McClead RE, Purohit DM, Palmer EA. 28-day survival rates of 6676 neonates with birth
weights of 1250 grams or less. Pediatrics 1991;87:7-17.
Phelps DL, Phelps CE. Cryotherapy in infants with retinopathy of prematurity: a decision model for treating one or both eyes. JAMA
1989;261:1751-1756.
Quinn GE, Dobson V, Kivlin J, Kaufman LM, Repka MX, Reynolds JD, Gordon RA, Hardy RJ, Tung B, Stone RA, for the
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Prevalence of myopia between 3 months and 5½ years in preterm
infants with and without retinopathy of prematurity. Ophthalmology 1998;105:1292-1300.
Quinn GE, Dobson V, Hardy RJ, Tung B, Phelps DL, Palmer EA, for the CRYO-ROP Cooperative Group. Visual fields measured
with double-arc perimetry in eyes with threshold retinopathy of prematurity (ROP) from the CRYO-ROP trial. Ophthalmology
1996;103:1432-1437.
Quinn GE, Dobson V, Barr CC, Davis BR, Palmer EA, Robertson J, Summers CG, Trese MT, Tung B, on behalf of the Cryotherapy
for Retinopathy of Prematurity Cooperative Group. Visual acuity of eyes after vitrectomy for ROP: Follow-up at 5½ years.
Ophthalmology 1996;103:595-600.
Quinn GE, Dobson V, Davitt BV, Hardy RJ, Tung B, Pedroza C, Good WV on behalf of the Early Treatment for Retinopathy of
Prematurity Cooperative Group. Progression of Myopia and High Myopia in the Early Treatment for Retinopathy of Prematurity
Study: Findings to 3 Years of Age. Ophthalmology 2007. In press.
Quinn GE, Dobson V, Biglan A, Evans J, Plotsky D, Hardy RJ, for the Cryotherapy for Retinopathy of Prematurity Cooperative
Group. Correlation of retinopathy of prematurity in fellow eyes in the CRYO-ROP study. Arch Ophthalmol 1995;113:469-473.
Quinn GE, Dobson V, Repka MX, Reynolds J, Kivlin J, Davis B, Buckley E, Flynn JT, Palmer EA. Development of myopia in infants
with birth weights less than 1251 grams. Ophthalmology 1992;99:329-340.
Quinn GE, Dobson V, Barr CC, Davis BR, Flynn JT, Palmer EA, Robertson J, Trese MT. Visual acuity in infants after vitrectomy for
severe retinopathy of prematurity. [Published erratum appears in Ophthalmology 1991;98:1005]. Ophthalmology 1991;98:5-13.
Reynolds J, Hardy RJ, Kennedy KA, Spencer R, van Heuven WAJ, Fielder AR. Lack of efficacy of light reduction in preventing
retinopathy of prematurity. N Engl J Med 1998;338:1572-1576.
Reynolds J, Dobson V, Flynn JT, Gilbert WS, Quinn GE, Tung B, Robertson J, Flynn JT for the Cryotherapy for Retinopathy of
Prematurity Group. Prediction of visual function in eyes with mild to moderate posterior pole residua of Retinopathy of Prematurity.
Arch Ophthalmol 1993;111:1050-1056.
Repka MX, Summers CG, Palmer EA, Dobson V, Tung B, Davis B, on behalf of the Cryotherapy for Retinopathy of Prematurity
Cooperative Group. The incidence of ophthalmological interventions in children with birth weights less than 1251 grams: Results
through 5½ years of age. Ophthalmology 1998;105:1621-1627.
Repka MX, Hardy RJ, Phelps DL, Summers CG. Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol
1993;111:618-620.
Repka MX, Tung B, Good WV, Shapiro M, Capone A, Baker JD, Barr CC, Phelps DL, van Heuven WAJ. Outcome of eyes
developing retinal detachment during the early treatment for retinopathy of prematurity study (ETROP). Arch Ophthalmol
2006;124:24-30.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 18
Reynolds JD, Hardy RJ, Kennedy KA, Spencer R, van Heuven WAJ, Fielder AR. Lack of Efficacy of Light Reduction in Preventing
Retinopathy of Prematurity. N Engl J Med 1998;338:1572-1576.
Saunders RA, Donahue ML, Christmann LM, Pakalnis AV, Tung B, Hardy RJ, Phelps DL. Racial variation in retinopathy of
prematurity. Arch Ophthalmol 1997;115:604-608.
Schaffer DB, Palmer EA, Plotsky DF, Metz HS, Flynn JT, Tung B, Hardy RJ, on behalf of The Cryotherapy for Retinopathy of
Prematurity Cooperative Group. Prognostic factors in the natural course of retinopathy of prematurity. Ophthalmology 1993;100:230236.
Summers GC, Phelps DL, Tung B, Palmer EA. Ocular cosmesis in retinopathy of prematurity. Arch Ophthalmol 1992;110:10921097.
The Early Treatment for Retinopathy of Prematurity Cooperative Group. The early treatment for retinopathy of prematurity study
(ETROP): structural findings at 2 years of age. Br J Ophthalmol 2006;90:1378-1382.
Trainor S, White GL, Kivlin JD, Thiese SM, Trunnell E. Follow-up retrospective study of compliance with a standard of care for
retinopathy of prematurity in one neonatal intensive care unit. J Ped Ophthalmol Strabismus 1989;26:285-287.
Trainor S, White GL, Trunnel E, Kivlin J. Compliance with a standard of care for retinopathy of prematurity in one neonatal intensive
care unit. J Ped Ophthalmol Strabismus 1988;25:237-239.
Trueb L, Evans J, Hammel A, Bartholomew P, Dobson D. Assessing visual acuity of visually impaired children using the Teller
acuity card procedure. Am Orthoptic J 1992;42:149-154.
VanderVeen DK, Coats DK, Dobson V, Fredrick D, Gordon RA, Hardy RJ, Neely DE, Palmer EA, Steidl SM, Tung B, Good WV on
behalf of the Early Treatment for Retinopathy of Prematurity Cooperative Group. The prevalence and course of strabismus in the
first year of life for infants with prethreshold ROP: findings from the early treatment for retinopathy of prematurity study. Arch
Ophthalmol 2006;124:24-30.
Watzke RC, Robertson JE, Palmer EA, Wallace PR, Evans MS, Delaney Soldevilla JE. Photographic grading in the retinopathy of
prematurity trial. Arch Ophthalmol 1990;108:950-955.
Beta-Blocker Heart Attack Trial (BHAT) Publications
Bell RL, Curb JD, Friedman LM, Payne GH. Termination of clinical trials: The Beta-Blocker Heart Attack Trial and the Hypertension
Detection and Follow-up Program experience. Control Clin Trials 1985;6:102-111.
Bell RL, Curb JD, Friedman LM, Mclntyre KM, Payton-Ross C, and the BHAT Research Group. Enhancement of visit adherence in
the national Beta-Blocker Heart Attack Trial. Control Clin Trials 1985;6:89-101.
Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. Il.
Morbidity results. JAMA 1983;250:2814-2819.
Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. 1.
Mortality results. JAMA 1982;247:1707-1714.
Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial: design features. Control Clin Trials 1981;2:275-285.
Beta-Blocker Heart Attack Study Group. The Beta-Blocker Heart Attack Trial. JAMA 1981;246:2073-2074.
Byington RP, Curb JD, Mattson ME, for the Beta-Blocker Heart Attack Trial Research Group. Assessment of double-blindness at
the conclusion of the Beta-Blocker Heart Attack Trial. JAMA 1985;253:1733-1736.
Byington RP and Goldstein S, for the BHAT Research Group. The association of digitalis therapy with mortality in survivors of acute
myocardial infarction: observations in the Beta -Blocker Heart Attack Trial. J Am Coll Cardiol 1985;6:976-982.
Byington RP, for the Beta -Blocker Heart Attack Trial Research Group. Beta-Blocker Heart Attack Trial: design, methods and
baseline results. Control Clin Trials 1984;5:382-437.
Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart
failure. Circulation 1986;73:503-510.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 19
Chiang YK, Hardy RJ, Hawkins CM, Kapadia AS. An illness-death process with time-dependent covariates. Biometrics 1989;45:669681.
DeMets DL, Hardy RJ, Friedman LM, Lan KKG: Statistical aspects of early termination in the Beta-Blocker Heart Attack Trial.
Control Clin Trials 1984;5:362-372.
Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E, for the Beta-Blocker Heart Attack Trial Research
Group: Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. J Am Coll Cardiol 1986;7:1-8.
Friedman LM, Byington RP and the Beta-Blocker Heart Attack Trial Research Group. Assessment of angina pectoris after
myocardial infarction: comparison of "Rose Questionnaire" with physician judgment in the Beta-Blocker Heart Attack Trial. Am J
Epidemiol 1985;121:555-562.
Furberg CD, Hawkins CM, Lichstein E, for the Beta-Blocker Heart Attack Trial Study Group. Effect of propranolol in postinfarction
patients with mechanical or electrical complications. Circulation 1984;69:761-765.
Furberg CD, Byington RP, for the Beta-Blocker Heart Attack Trial Research Group. What do subgroup analyses reveal about
differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. Circulation 1983;67(Suppl 1):98101.
Goldstein S, for the BHAT Research Group: Propranolol therapy in patients with acute myocardial infarction: The Beta-BIocker
Heart Attack Trial. Circulation 1983;67(Suppl 1):53-57.
Green D, Rossi EC, Haring 0. The Beta-Blocker Heart Attack Trial: studies of platelets and Factor VIII. Thromb Res 1982;28:261267.
Hawkins CM, Richardson DW, Vokonas PS, for the Beta-Blocker Heart Attack Trial Research Group: Effect of propranolol in
reducing mortality in older myocardial infarction patients--The Beta-Blocker Heart Attack Trial experience. Circulation 1983;67(Suppl
1):94-97.
Haywood LJ, for the BHAT Research Group. Coronary heart disease mortality/morbidity and risk in blacks. 1. Clinical manifestation
and diagnostic critera: the experience of the Beta-Blocker Heart Attack Trial. Am Heart J 1984;108:787-793.
Howard JM, DeMets D, and The BHAT Research Group: How informed is informed consent? Control Clin Trials 1981;2:287-303.
Lichstein E, Morganroth J, Harrist R, Hubble E, for the BHAT Study Group. Effect of propranolol on ventricular arrhythmia: The BetaBlocker Heart Attack Trial experience. Circulation 1983;67(Suppl 1):5-10.
Mattson ME, Curb JD, MCArdle R and the AMIS and BHAT Research Groups. Participation in a clinical trial: the patients' point of
view. Control Clin Trials 1985;6:156-167.
Morganroth J, Lichstein E, Byington RP, for the BHAT Study Group. Beta-Blocker Heart Attack Trial: impact of propranolol therapy
on ventricular arrhythmia. Prev Med 1985;14:346-357.
Peters RW, Byington R, Arensberg D, Friedman L, Romhilt DW, Barker A, Laubach C, Wilner GW, Goldstein S, for the BHAT
Research Group. Mortality in the Beta-Blocker Heart Attack Trial: the circumstances surrounding death. J Chronic Dis 1987;40:7582.
Ruberman W, Weinblatt E, Goldberg JD, Chaudhary BS. PsychosociaI influences on mortality after myocardial infarction. N Engl J
Med 1984;311:552-559.
Shulman RS, Herbert PN, Capone RJ, MCClure D, Hawkins CM, Henderson LO, Saritelli A, Campbell J. Effects of propranolol on
blood lipids and lipoproteins in myocardial infarction. Circulation 1983;67(Suppl 1):19-21.
Walle T, Byington RP, Furberg CD, McIntyre K, Vokonas P. Biologic determinants of propranolol disposition: results from 1308
patients in the Beta-Blocker Heart Attack Trial. J Clin Pharm Ther 1985;38:509-518.
Dietary Intervention Study of Hypertension (DISH) Publications
Blaufox MD, Langford HG, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy
JD, Hotchkiss J, Tyler M. The Dietary Intervention Study of Hypertension (DISH). Cardiovasc Rev Rep 1985;6:1036-1052.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 20
Blaufox MD, Langford HG, Oberman A, Hawkins CM, Wassertheil-Smoller SW, Cutter GR. Effect of dietary change on the return of
hypertension after withdrawal of prolonged antihypertensive therapy (DISH). Dietary Intervention Study of Hypertension. J
Hypertens 1984;2(Suppl):S179-S181.
Ho GY, Blaufox MD, Wassertheil-Smoller S, Oberman A, Langford H. Plasma renin predicts success of antihypertensive drug
withdrawal. Am J Hypertens 1994;7:679-684.
Langford HG. Step-down therapy for hypertension. Effect of weight reduction and sodium restriction on success. Postgrad Med
1985;77:100-105, 108-110.
Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy
JD, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985;253:657-664.
Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy
JD, et al. Return of hypertension after withdrawal of prolonged antihypertensive therapy, effect of weight loss, sodium reduction, and
baseline factors. Trans Assoc Am Physicians 1984;97:190-196.
Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy
JD, et al. Does effective antihypertensive therapy partially "cure" hypertension? Trans Am Clin Clinatol Assoc 1984;96:111-119.
Thaler L, Wassertheil-Smoller S, Blaufox MD, Oberman A, Langford HG. Effect of withdrawal of antihypertensive drug on depressive
mood. Am J Hypertens 1993;6:1055-1062.
Wassertheil-Smoller S, Blaufox MD, Langford HG, Oberman A, Cutter G, Pressel S. Prediction of response to sodium intervention
for blood pressure control. J Hypertens 1986;4(Suppl 5):S343-S346.
Wassertheil-Smoller S, Langford HG, Blaufox MD, Oberman A, Hawkins M, Levine B, Cameron M, Babcock C, Pressel S, Caggiula
A, et al. Effective dietary intervention in hypertensives: sodium restriction and weight reduction. J Am Diet Assoc 1985;85:423-430.
Wassertheil-Smoller, Langford HG, Blaufox MD, Oberman A, Hawkins M. Diuretics and salt restriction in blood pressure control.
Curr Concepts Nutr 1983;12:175-189.
Hypertension Detection and Follow-up Program Publications
Abernethy J, Borhani NO, Hawkins CM, Crow R, Entwisle G, Jones JW, Maxwell MH, Langford HG, Pressel S. Systolic blood
pressure as an independent predictor of mortality in the HDFP. Am J Prev Med 1986;2:123-132.
Apostolides A, Cutter G, Daugherty SA, Detels R, Kraus J, Wassertheil-Smoller S, Ware J. Three-year incidence of hypertension in
thirteen US communities. Prev Med 1982;11:487-499.
Apostolides AY, Cutter G, Kraus JF, Oberman A, Blaszkowski T, Borhani NO, Entwisle G. Impact of hypertension information on
high blood pressure control between 1973 and 1978. Hypertension 1980;2:708-713.
Apostolides A, Schnaper H, Stamler R, Taylor J, Tyler M, Wassertheil-Smoller S for the HDFP Cooperative Group. Patient
participation in a hypertension control program. JAMA 1978;239:1507-1514.
Apostolides A, Blaufox MD, Borhani NO, Cutter G, Daugherty S, Lewin AJ, Polk BF for the HDFP Cooperative Group. Mild
hypertensives in the HDFP. Ann N Y Acad Sci 1978; 304:254-266.
Bell RL, Curb JD, Friedman LM, Payne GH. Termination of clinical trials: The BHAT and the HDFP experience. Control Clin Trials
1985;6:102-111.
Blaufox MD, Curb JD, Kralios A, Polk BF, Tyler M for the HDFP Cooperative Group. Therapeutic control of blood pressure in the
HDFP. Prev Med 1979;8:2-13.
Borhani NO, Blaufox MD, Oberman A, Polk BF. Incidence of coronary heart disease and left ventricular hypertrophy in the HDFP.
Prog Cardiovasc Dis 1986;29:55-62.
Borhani NO, Langford HG, Hawkins CM, Curb JD (Letter to the Editor). Treatment for mild hypertension. N Engl J Med
1983;308:524-525.
Borhani NO. The Hypertension Detection and Follow-up Program. In: Onesti G, Klimt CR, editors. Hypertension: Determinants,
Complications, and Intervention: the Fifth Hahnemann International Symposium on Hypertension; 1977; Philadelphia. New York:
Grune & Stratton, Inc.; 1979. p.405-414.
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 21
Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J for the HDFP Cooperative Group. The Hypertension
Detection and Follow-up Program. Prev Med 1976;5:207-215.
Castle CH, Daugherty S, Detels R, Hawkins CM, Krishan I, Oberman A, Wassertheil-Smoller S for the HDFP Cooperative Group.
Blood pressure studies in 14 communities: A two-stage screen for hypertension. JAMA 1977; 237:2385-2391.
Cooper SP, Ford CE, Hardy RJ, Davis BR, Hawkins CM, Labarthe DR (Letter to the Editor). Regarding "Goals of antihypertensive
therapy: is there a point beyond which pressure reduction is dangerous?" Am J Hypertens 1990;3:733-734.
Cooper SP, Hardy RJ, Labarthe DR, Hawkins CM, Smith EO, Blaufox MD, Cooper C, Entwisle G, Maxwell MH, on behalf of the
HDFP Cooperative Group. The relationship between degree of blood pressure reduction and mortality among hypertensives in the
HDFP. Am J Epidemiol 1988;127:387-403.
Cowan L, Detels R, Farber M, Lee ES, McCray G, O'Flynn S, Parnell MJ, on behalf of the HDFP Cooperative Group. Residential
mobility and long-term treatment of hypertension. J Comm Health 1980;5:159-166.
Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. Adverse effects of antihypertensive medications in the HDFP. Prog
Cardiovasc Dis 1986;29:73-88.
Curb JD, Borhani NO, Blaszkowski T, Zimbaldi N, Fotiu S, Williams W. Patient perceived side effects to antihypertensive drugs. Am
J Prev Med 1985;1:36-40.
Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of
antihypertensive drugs. JAMA 1985;253:3263-3268.
Curb JD, Borhani NO, Entwisle G, Tung B, Kass E, Schnaper H, Williams W, Berman R. Isolated systolic hypertension in 14
communities. Am J Epidemiol 1985;121:362-370.
Curb JD, Borhani NO, Schnaper H, Entwisle G, Kass E, Williams W, Berman R. Detection and treatment of hypertension in older
individuals. Am J Epidemiol 1985;121:371-376.
Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM. Ascertainment of vital status through the National Death Index
and the Social Security Administration. Am J Epidemiol 1985;121:754-766.
Curb JD, Ford CE, Hawkins CN, Smith EO, Zimbaldi N, Carter B, Cooper C. A coordinating center in a clinical trial: The HDFP.
Control Clin Trials 1983;4:171-186.
Curb JD, Labarthe DR, Cooper SP, Cutter GR, Hawkins CM. Training and certification of blood pressure observers. Hypertension
1983;5:610-614.
Curb JD, Babcock C, Pressel S, Tung B, Remington RD. Nosological coding of cause of death. Am J Epidemiol 1983;118:122-128.
Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. Reserpine and breast cancer in the HDFP. Hypertension 1982;4:307-311.
Curb JD, Hawkins CM, Ford CE (Letter to the Editor). Should mild hypertension be treated? N Engl J Med 1982;307:1522-1523.
Cutter G, Heyden S, Kasteler J, Kraus JF, Lee ES, Shipley T, Stromer M, on behalf of the Hypertension Detection and Follow-up
Program. Mortality surveillance in collaborative trials. Am J Public Health 1980;70:394-400.
Cutter G, Hebel JA, Labarthe D, Oberman A, Prineas R, Varady P for the HDFP Cooperative Group. Variability of blood pressure
and the results of screening in the HDFP. J Chronic Dis 1978;31:651-667.
Daugherty SA. Mortality findings beyond five years in the Hypertension Detection and Follow-up Program. J Hypertens
1988;6(Suppl 4):597-601.
Daugherty SA, Berman R, Entwisle G, Haerer AF. Cerebrovascular events in the HDFP. Prog Cardiovasc Dis 1986;29:63-72.
Davis BR, Curb JD, Borhani NO, Prineas RJ, Molteni A, for the HDFP Cooperative Group. Coffee consumption and serum
cholesterol in the HDFP. Am J Epidemiol 1988;128:124-136.
Davis BR, Curb JD, Tung B, Hawkins CM, Ehrman S, Farmer J, Martin M. Standardized physician preparation of death certificates.
Control Clin Trials 1987;8:110-120.
Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman N. The association of postural changes in systolic blood pressure
UTSPH CCCT Bibliography
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 22
and mortality in persons with diastolic hypertension: The HDFP experience. Circulation 1987;75:340-346.
Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. HDFP design, methods, and baseline characteristics and blood
pressure response of the study participants. Prog Cardiovasc Dis 1986;29:11-28.
Ford CE, Langford HG, Palmer M. Recruitment in the HDFP. Control Clin Trials 1987;8(Suppl)54-67.
Hardy RJ, Hawkins CM. The impact of selected indices of antihypertensive therapy on all cause mortality. Am J Epidemiol
1983;117:566-574.
Hardy RJ, Cutter GR, Hawkins CM. Letter to the Editor: Sodium excretion and sympathetic activity in relation to severity of
hypertensive disease. Lancet 1976;2:471.
Harlan LC, Polk BF, Cooper S, Blaszkowski TP, Ignatius-Smith J, Stromer M, Mull H. Effects of labeling and treatment of
hypertension on perceived health. Am J Prev Med 1986;2:256-261.
HDFP Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection
and Follow-up Program. JAMA 1988;259:2113-2122.
HDFP Cooperative Group. Education level and five-year all cause mortality in the HDFP. Hypertension 1987;9:641-646.
HDFP Cooperative Group. Five-year findings of the HDFP: Prevention and reversal of left ventricular hypertrophy with
antihypertensive drug therapy. Hypertension 1985;7:105-112.
HDFP Cooperative Group. Mortality findings for stepped-care and referred-care participants in the HDFP, stratified by other risk
factors. Prev Med 1985;14:312-335.
HDFP Editorial Review and Publications Committee (Letter to the Editor). Impact on interracial comparisons of inappropriate criteria
for cardiac enlargement in blacks. Hypertension 1985;7:1033.
HDFP Cooperative Group. Effect of stepped care treatment on incidence of myocardial infarction and angina pectoris. Five-year
findings of the HDFP. Hypertension 1984; 6(Suppl 1):198-206.
HDFP Cooperative Group. Five-year findings of the HDFP: Mortality by race-sex and blood pressure level. A further analysis. J
Comm Health 1984;9:314-327.
HDFP Cooperative Group. The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic
abnormalities at baseline: The HDFP experience. Circulation 1984;70:996-1003.
HDFP Cooperative Group. Five-year findings of the HDFP: III. Reduction in stroke incidence among persons with high blood
pressure. JAMA 1982;247:633-638.
HDFP Cooperative Group. The effect of treatment on mortality in "mild" hypertension-results of the HDFP. N Engl J Med 1982;307:
976-980.
HDFP Cooperative Group (Letter to the Editor). Hypertension Detection and Follow-up Program. JAMA 1980;244:1318.
HDFP Cooperative Group. Five-year findings of the HDFP: I. Reduction in mortality of persons with high blood pressure, including
mild hypertension. JAMA 1979;242:2562-2571.
HDFP Cooperative Group. Five-year findings of the HDFP: II. Mortality by race-sex and age. JAMA 1979;242:2572-2577.
HDFP Cooperative Group. The Hypertension Detection and Follow-up Program: A progress report. Circ Res 1977;40(Suppl
1):106-109.
Heyden S, Borhani NO, Tyroler HA, Schneider KA, Langford HG, Hames CG, Hutchinson R, Oberman A. The relationship of weight
and changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension. J Chronic Dis
1985;38:281-288.
Heymsfield S, Kraus JF, Lee ES, McDill M, Stamler R, Watson R for the HDFP Cooperative Group. Race, education and prevalence
of hypertension. Am J Epidemiol 1977;106:351-361.
Hypertension Detection and Follow-up Program.
participants. Hypertension 1983;5(Suppl 4):1-205.
UTSPH CCCT Bibliography
Baseline characteristics of the enumerated, screened, and hypertensive
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 23
Implications of the HDFP. Prog Cardiovasc Dis 1986;29:3-10.
Kraus JF, Conley A, Hardy RJ, Sexton M, Sweezey Z. Relationship of demographic characteristics of interviewers to blood pressure
measurements. J Comm Health 1982;8:3-12.
Labarthe DR. Mild hypertension: The question of treatment. Annu Rev Public Health 1986;7:193-215.
Labarthe DR, Hawkins CM, Remington RD. Evaluation of performance of selected devices for measuring blood pressure. Am J
Cardiol 1973;32:546-553.
Langford HG, Curb JD, Pressel S, Schneider KA. Effect of thiazide-based therapy on serum alkaline phosphatase. J Hum Hypertens
1991; 5:333-338.
Langford HG. Mortality at eight years for Hypertension Detection and Follow-up Program participants. In: Strasser T, Ganten D,
editors. Mild Hypertension: From Drug Trials to Practice;1985 Dec 4-7; Konigstein, FRG. New York: Raven Press; 1987; p.45-52.
Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Pressel S. Is thiazide-produced uric acid elevation harmful? Analysis of
data from the HDFP. Arch Intern Med 1987;147:645-649.
Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. All-cause mortality in the HDFP: Findings for the whole cohort and for
persons with less severe hypertension, with and without other traits related to risk of mortality. Prog Cardiovasc Dis 1986;29:29-54.
Langford HG, Oberman A, Borhani NO, Entwisle G, Tung B. Black-white comparison of indices of coronary heart disease and
myocardial infarction in the stepped-care cohort of the HDFP. Am Heart J 1984;108:797-801.
Langford HG, Payne G, Remington RD, Stamler J. The Hypertension Detection and Follow-up Program. In: Oglesby P, editor.
Epidemiology and control of hypertension: papers and discussions from the 2 nd International Symposium on the Epidemiology of
Hypertension presented Sept. 1974; Chicago. New York: Stratton Intercontinental Medical Book Corporation; 1975. p.663-672.
Lewin A, Blaufox MD, Castle H, Entwisle G, Langford HG. Apparent prevalence of curable hypertension in the HDFP. Arch Intern
Med 1985;145:424-427.
Martin JB, Annegers JF, Curb JD, Heyden S, Howson C, Lee ES, Lee M, on behalf of the HDFP Cooperative Group. Mortality
patterns among hypertensives by reported level of caffeine consumption. Prev Med 1988;17:310-320.
Maxwell MH, Ford CE. Cardiovascular morbidity and mortality in the HDFP patients 50-69 years old at entry. J Cardiovasc
Pharmacol 1985;7(Suppl 2):5-9.
Morris DL, Borhani NO, Fitzsimmons E, Hardy RJ, Hawkins CM, Kraus J, Labarthe DR, Mastbaum L, Payne GH. Serum cholesterol
and cancer in the HDFP. Cancer 1983;52:1754-1759.
Polk BF, Harlan LC, Cooper SP, Stromer M, Ignatius J, Mull H, Blaszkowski TP. Disability days associated with detection and
treatment in a hypertension control program. Am J Epidemiol 1984;119:44-53.
Remington RD, on behalf of the HDFP Cooperative Group. The Hypertension Detection and Follow-up Program. INSERM 1973;
21:185-194.
Results and implications of the Hypertension Detection and Follow-up Program. Prog Cardiovasc Dis 1986;29(Suppl 1):1-124.
Schneider KA, Heyden S, Ford CE. Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment
in the reduction of CHD. Evidence from the HDFP. Nephron 1987;47(Suppl 1):104-107.
Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and the
effect of treatment of hypertension on renal function. Results from the HDFP. Hypertension 1989;13(Suppl 1):80-93.
Shulman N, Cutter G, Daugherty R, Sexton M, Pauk G, Taylor MJ, Tyler M. Correlates of attendance and compliance in the HDFP.
Control Clin Trials 1982:3:13-27.
Smith EO, Curb JD, Hardy RJ, Hawkins CM, Tyroler HA. Clinic attendance in the HDFP. Hypertension 1982;4:710-715.
Smith EO, Hardy RJ, Cutter GR, Curb JD, Hawkins CM. Application of survival analysis techniques to evaluation of factors affecting
compliance in a clinical trial of hypertension control. Control Clin Trials 1980;1:59-69.
Smith EO, Hardy J, Cooper CJ, Hawkins CM.
1980;12:129-149.
UTSPH CCCT Bibliography
Two-compartment Markov regression analysis. Comput Prog Biomed
Updated 22 Oct 07
UT School of Public Health
COORDINATING CENTER FOR CLINICAL TRIALS
Page 24
Smith EO, Hardy RJ, Cutter GR. A two-compartment regression model applied to compliance in a hypertension treatment program.
J Chronic Dis 1980;33:645-651.
Stamler R, Ford CE, Stamler J. Why do lean hypertensives have higher mortality rates than other hypertensives? Findings from the
Hypertension Detection and Follow-up Program. Hypertension 1991;17:553-564.
Stamler R, Gosch FC, Stamler J, Lindberg HA, Hilker RJ. A hypertension control program based on the workplace: Report on the
Chicago center. J Occup Med 1978;20:618-625.
Stamler J, Berkson DM, Gosch FC, Hilker RJ, Lindberg HA, Schoenberger JA, Shekelle RB, Stamler R. The new national
cooperative Hypertension Detection and Follow-up Program. Chicago Med 1973;76.
Taylor JO, Borhani NO, Entwisle G, Farber M, Hawkins CM. Hypertension detection and follow-up program. Summary of the
baseline characteristics of the hypertensive participants. Hypertension 1983;5:44-50.
Tyroler HA, Ford CE. Serum cholesterol and Coronary Heart Disease risk in female and older hypertensives: The experience under
usual community care in the Hypertension Detection and Follow-up Program. Ann Epidemiol 1992;2:155-160.
Tyroler HA. Race, education and five-year mortality in HDFP stratum I referred-care males. In: Strasser T, Gross R, editors. Mild
Hypertension: Recent Advances; 1982 Sep 27-30; Burgenstock, Switzerland. New York: Raven Press; 1983. p.163-175.
Walker WG, Ford CE. At risk nephrons and the decline in renal function in response to treatment of hypertension. Trans Am Clin
Climatol Assoc 1995;107:134-145.
Wassertheil-Smoller S, Apostolides A, Miller M, Oberman A, Thom T, on behalf of the Hypertension Detection and Follow-up
Program. Recent status of detection, treatment and control of hypertension in the community. J Community Health 1979;5:82-93.
Willett WC, Polk BF, Underwood BA, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider KA, Hames CG, on behalf of the
HDFP Cooperative Group. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N Engl J Med
1984;310:430-434.
Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider KA, Hames CG. Prediagnostic serum
selenium and risk of cancer. Lancet 1983;1:130-134.
Williams WR, Schneider KA, Borhani NO, Schnaper HW, Slotkoff LM, Ellefson RD. The relationship between diuretics and serum
cholesterol in HDFP participants. Am J Prev Med 1986;2:248-255.
UTSPH CCCT Bibliography
Updated 22 Oct 07